Article
Gilead's Dan O'Day pulls the plug on the lion's share of their filgotinib collaboration as th
Rating:
0.0
Views:
109
Likes:
1
Library:
1
Five years after Gilead plunked down $725 million in cash to partner with Galapagos on filgotinib, new CEO Dan O'Day has opted to shelve the rheumatoid arthritis program and all but a much smaller piece of the old development plan in the US. The big biotech said Tuesday afternoon that
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value